Acumen Pharmaceuticals, Inc. Share Price & Technical Analysis
ABOS · $2.42 (-3.59%)
Healthcare / Biotechnology
$2.42
-3.59%
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement …
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
4% return in May, 2% avg return in past 3 year May month.
29% return in 2026, 1% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 24% | 24% | -23% | 0% | 4% | – | – | – | – | – | – | – | 29% |
| 25 | -17% | -13% | -15% | 0% | -9% | 20% | 17% | 0% | 21% | 22% | -14% | 11% | 23% |
| 24 | -16% | 34% | -5% | -22% | -9% | -20% | 38% | -18% | -7% | 16% | -21% | -26% | -56% |
| 23 | 29% | -22% | -23% | -5% | 26% | -2% | 51% | -18% | -30% | -55% | 26% | 58% | 37% |
| 22 | -26% | 16% | -34% | 0% | -8% | 31% | 15% | 6% | 79% | -31% | -21% | -5% | 20% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Emerging · Neutral
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$177.68M
P/E ratio
—
52W high
$3.60
52W low
$0.99
Volume
2,87,758
Beta
0.32
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Acumen Pharmaceuticals, Inc. share price today?
- Acumen Pharmaceuticals, Inc. (ABOS) last traded around $2.42 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ABOS have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ABOS. Download the app for real-time alerts.
- How can I analyze Acumen Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.